<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04202705</url>
  </required_header>
  <id_info>
    <org_study_id>SYD1875.001</org_study_id>
    <nct_id>NCT04202705</nct_id>
  </id_info>
  <brief_title>A First-in-human Dose-escalation and Expansion Study With the Antibody-drug Conjugate SYD1875</brief_title>
  <official_title>A First-in-human Dose-escalation and Expansion Study With the Antibody-drug Conjugate SYD1875 to Evaluate the Safety, Pharmacokinetics and Efficacy in Patients With 5T4-expressing Locally Advanced or Metastatic Solid Tumours</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Byondis B.V.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Byondis B.V.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is the first-in-human study with SYD1875, an antibody-drug conjugate (ADC) comprising of&#xD;
      a humanized IgG1 monoclonal antibody directed against the 5T4 oncofetal antigen covalently&#xD;
      conjugated to a duocarmycin-based linker-drug. This study includes a dose-escalation part&#xD;
      (Part 1) in which the maximum tolerated dose (MTD) and recommended dose for expansion (RDE)&#xD;
      will be determined, and an expansion part (Part 2) to evaluate efficacy and safety in&#xD;
      specific patient cohorts.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Cancer cells can have different kinds of proteins on their cell surface; one of these is the&#xD;
      oncofetal antigen 5T4. 5T4 plays an important role in the development of cancer. Currently no&#xD;
      drugs are available that work via the 5T4 antigen.&#xD;
&#xD;
      The new cancer drug SYD1875 is being developed by Byondis B.V. SYD1875 is an antibody-drug&#xD;
      conjugate and consists of two parts: an antibody and a linker-drug moiety containing a toxin.&#xD;
      The antibody part binds to 5T4 on the surface of the cancer cell. When SYD1875 binds to this&#xD;
      cancer cell, it will be internalized by the cell. After proteolytic cleavage of the linker,&#xD;
      the toxin will be split off in the cell and the cancer cell will be killed. Thus, SYD1875 can&#xD;
      be considered as a form of targeted chemotherapy.&#xD;
&#xD;
      This is the first study in which SYD1875 is administered to humans. The study consists of two&#xD;
      parts:&#xD;
&#xD;
      Part 1 is the dose-escalation part in which a low dose of SYD1875 is given to cancer&#xD;
      patients. If it is well tolerated, a higher dose of SYD1875 will be given to other cancer&#xD;
      patients until the maximum tolerated dose is reached.&#xD;
&#xD;
      In Part 2 of the study, groups of patients with a specific type of cancer will receive the&#xD;
      SYD1875 dose which has been selected for further evaluation.&#xD;
&#xD;
      All patients from both parts of the study will receive SYD1875 infusions every three weeks&#xD;
      until progression of the cancer or unacceptable toxicity develops.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 28, 2020</start_date>
  <completion_date type="Anticipated">January 2024</completion_date>
  <primary_completion_date type="Anticipated">January 2023</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of dose-limiting toxicities</measure>
    <time_frame>21 days</time_frame>
    <description>Part 1</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Objective response rate</measure>
    <time_frame>21 days</time_frame>
    <description>Part 2</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">90</enrollment>
  <condition>Solid Tumor</condition>
  <arm_group>
    <arm_group_label>SYD1875</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>5T4-targeting Antibody-Drug Conjugate</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SYD1875</intervention_name>
    <description>SYD1875 IV (in the vein) infusion every three weeks. Number of cycles: until cancer progression or unacceptable toxicity develops. Different doses.</description>
    <arm_group_label>SYD1875</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Main Inclusion Criteria:&#xD;
&#xD;
          -  Patient with histologically-confirmed, locally advanced or metastatic cancer who has&#xD;
             progressed on standard therapy or for whom no standard therapy exists, with the&#xD;
             following restriction:&#xD;
&#xD;
          -  Part 1: solid tumours of any origin&#xD;
&#xD;
          -  Part 2: three patient cohorts&#xD;
&#xD;
          -  Tumour 5T4 membrane staining according protocol&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group (ECOG) performance status ≤ 1;&#xD;
&#xD;
          -  Adequate organ function&#xD;
&#xD;
          -  For Part 2: measurable disease&#xD;
&#xD;
        Main Exclusion Criteria:&#xD;
&#xD;
          -  Having been treated with:&#xD;
&#xD;
               1. 5T4-targeting therapy at any time&#xD;
&#xD;
               2. Trastuzumab duocarmazine (SYD985) at any time&#xD;
&#xD;
               3. Other anticancer therapy within 4 weeks or as defined in the protocol&#xD;
&#xD;
               4. Hormone therapy within 1 week&#xD;
&#xD;
          -  History or presence of keratitis, clinically significant renal disease, lung disease,&#xD;
             or cardiovascular disease as specified in the protocol&#xD;
&#xD;
          -  Symptomatic brain metastases, brain metastases requiring steroids or treatment for&#xD;
             brain metastases within 8 weeks&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ellen Mommers, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Byondis B.V., The Netherlands</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ellen Mommers, PhD</last_name>
    <phone>+31 (0)24 679 5100</phone>
    <email>clinicaltrials@byondis.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Institut Jules Bordet</name>
      <address>
        <city>Brussels</city>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nuria Kotecki, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Institut Bergonié</name>
      <address>
        <city>Bordeaux</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antoine Italiano, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre Oscar Lambret</name>
      <address>
        <city>Lille</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nicolas Penel, MD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>France</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>December 12, 2019</study_first_submitted>
  <study_first_submitted_qc>December 16, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">December 17, 2019</study_first_posted>
  <last_update_submitted>July 20, 2021</last_update_submitted>
  <last_update_submitted_qc>July 20, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 21, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>ADC</keyword>
  <keyword>5T4</keyword>
  <keyword>solid tumors</keyword>
  <keyword>duocarmycin</keyword>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

